Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMI-115 in Women With Moderate to Severe Endometriosis-Associated Pain
NCT07318688Phase 3Recruiting
- Sponsor
- HopeMed
- Start
- Jan 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of HMI-115 in endometriosis, sponsored by HopeMed. Started Jan 2026; status: recruiting.
02
Drugs
HMI-115
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT07318688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07318688.